导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.38% | 1395/4773 |
| 近一周 | 0.78% | 62/5462 |
| 近一月 | 5.64% | 55/5421 |
| 近一季 | 5.71% | 257/5209 |
| 近半年 | 6.96% | 642/4920 |
| 近一年 | 4.08% | 1798/4366 |
| 近两年 | 39.92% | 1902/2954 |
| 近三年 | 48.10% | 567/2253 |
| 成立以来 | 56.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.71% 2874/4961 |
-7.78% 3803/5312 |
- - |
- - |
| 2025 | 10.12% 2830/4813 |
2.50% 1356/3635 |
11.57% 161/4076 |
-8.60% 4054/4524 |
5.35% 451/4813 |
| 2024 | 37.94% 44/3463 |
9.93% 99/2808 |
6.77% 136/3014 |
11.79% 2462/3129 |
5.14% 633/3463 |
| 2023 | -1.86% 540/2656 |
-2.22% 1944/2280 |
2.12% 163/2385 |
4.87% 118/2515 |
-6.28% 1706/2655 |
| 2022 | -4.28% 86/2207 |
2.19% 75/1919 |
-1.28% 1699/2016 |
-8.03% 163/2113 |
3.17% 757/2208 |
| 2021 | 3.93% 596/1822 |
10.75% 29/1255 |
-0.20% 1131/1330 |
-5.59% 830/1466 |
-0.40% 1232/1822 |
| 2020 | 6.13% 875/1250 |
-11.80% 854/1028 |
3.74% 930/1067 |
5.06% 932/1164 |
10.40% 598/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证银行ETF联接C VS. 长安沪深300非周期A(740101) |